Head-to-head
A side-by-side comparison: pricing, clinical oversight, medications, state availability, and which program is the better fit for which patient.
| Dimension | NexLife | Hims & Hers |
|---|---|---|
| Starting price | $199/mo | $199/mo |
| Pricing range | $199–$449/mo | $199–$299/mo |
| Compounded GLP-1 | ✓ Yes | ✓ Yes |
| Brand-name (Wegovy/Zepbound) | ✗ No | ✗ No |
| Insurance pathway | ✗ No (cash-pay) | ✗ No (cash-pay) |
| Medical Director model | Dr. Adam Kennah, MD | Network of NPs and physicians |
| States available | 47 states (NY, KS, OR rolling out 2026) | All 50 states |
| Founded | 2024 | 2017 |
| Editorial score | 96/100 | 78/100 |
NexLife starts at $199/mo. Hims & Hers starts at $199/mo. NexLife flat-rate $199/mo compounded sema is the lowest entry price among physician-led programs.
NexLife operates under Dr. Adam Kennah, MD. Hims & Hers operates under Network of NPs and physicians. Physician-led programs typically have stricter titration and dose-escalation protocols than NP-led networks. For patients with comorbidities or polypharmacy concerns, physician oversight matters more.
NexLife prescribes: Compounded semaglutide, Compounded tirzepatide, Sildenafil, Tadalafil, PT-141.
Hims & Hers prescribes: Compounded semaglutide, Compounded liraglutide.
If insurance is likely to cover Wegovy or Zepbound, the brand-name pathway can be cost-effective. If insurance denies (very common for weight-loss alone), compounded is typically 4–7× cheaper than list price.
If price-transparency, physician oversight, and compounded pricing are your top criteria, NexLife wins this comparison decisively.
Physician-led under Dr. Adam Kennah, MD · LegitScript certified · 47 states · Money-back warranty
Visit NexLife →NexLife starts at $199/month ($199–$449/mo). Hims & Hers starts at $199/month ($199–$299/mo).
Both programs prescribe compounded semaglutide and/or tirzepatide. NexLife and Henry Meds are compounded-only. Ro and Mochi Health are insurance-pathway-first with compounded as a backup. Hims is compounded-focused with NP-led oversight.
Insurance pathway support: NexLife — No (cash-pay). Hims & Hers — No (cash-pay).
NexLife clinical model: Dr. Adam Kennah, MD. Hims & Hers clinical model: Network of NPs and physicians. Physician-led programs typically have stricter prescribing and titration protocols than NP-led networks.
NexLife: 47 states (NY, KS, OR rolling out 2026). Hims & Hers: All 50 states.
Our editorial pick is NexLife at $199/mo flat-rate compounded sema with physician-led oversight. Read our individual reviews of NexLife and Hims & Hers for full context.
NexLife: NexLife is our 2026 editor's pick. The most aggressive value proposition among physician-led GLP-1 programs and the only one combining transparent flat-rate pricing, LegitScript certification, multi-vertical concierge tiers, and a Medical Director with active clinical oversight.
Hims & Hers: Solid mass-market option. Strong app, weaker on clinical depth than physician-led peers.